US FDA Authorises Innovative Robotic System for Minimally Invasive Bladder Tumour Removal

The US Food and Drug Administration (FDA) has granted De Novo authorisation to an advanced robotic surgical system developed by Virtuoso Surgical for the minimally invasive removal of bladder tumours. The regulatory clearance marks a significant development in robotic-assisted urological procedures and introduces a new approach to treating bladder cancer.

The Virtuoso system incorporates two miniature robotic arms positioned at the tip of an endoscope. These independently controlled instruments enable surgeons to perform precise surgical movements within the bladder while accessing the treatment area through the urethra, eliminating the need for external incisions.

A key feature of the technology is its ability to facilitate en bloc resection, a technique that allows bladder tumours to be removed as a single, intact specimen rather than in multiple fragments. Preserving the tumour's structure can support more accurate pathological examination, potentially improving cancer diagnosis and staging.

The FDA's De Novo authorisation establishes a new regulatory classification for this type of electromechanical endoscopic surgical technology. The decision provides a regulatory pathway for innovative devices that do not have a substantially equivalent product already available in the market.

Virtuoso Surgical intends to introduce the system through a limited commercial launch at selected urology centres across the United States in 2027. This initial rollout will mark an important step towards integrating the technology into clinical practice.

The development reflects continuing advances in surgical robotics, particularly in designing compact instruments capable of performing complex procedures through natural body openings with greater precision and control.

10-11-2026